Opus Medical Therapies, LLC — SEC Form D Filing

Opus Medical Therapies, LLC filed an SEC Form D on September 22, 2026, reporting $485K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 22, 2026
Amount reported
$485K
Round stage
Seed stage, as a sub-half-million-dollar equity raise represents an early-stage capital injection typical of initial formulation and preclinical validation phases.
Industry
Biotechnology
Website
https://opusmedicaltherapies.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: GEORGIA

Problem

Patients suffering from chronic degenerative conditions lack targeted, biocompatible therapies that can actively repair damaged tissue without triggering severe immune responses.

Solution

Opus Medical Therapies develops advanced regenerative biomaterials and targeted therapeutic agents designed to restore damaged tissue function.

Why now

Recent breakthroughs in biocompatible materials and precision delivery systems now enable the localized administration of regenerative therapies directly to diseased tissues.

Source: SEC EDGAR Form D filing